ERBB2 and breast carcinoma: The KAMILLA study, a phase IIIb, one-arm, international, open-label study evaluated safety and tolerability (primary endpoints) and OS/PFS (secondary endpoints) of T-DM1 in advanced HER2-positive breast cancer patients pretreated with any chemotherapy and an anti-HER2 agent [10].